Desentum closes financial round totalling nearly EUR 2 million

Desentum, an Espoo, Finland-based biopharmaceutical company developing next generation immunotherapy to fight allergies, announced that it has completed a Series A financing round totalling EUR 1.85 million.

The participating investors include Belgian Cascara Ventures, Luxembourgian ACME Investments, Finnish VTT Ventures and Sto-Rahoitus, and the founding shareholders.

Desentum, led by CEO Pekka Mattila, will use most of the raised capital to produce the most prominent birch pollen hypoallergen under GMP conditions and to prepare for preclinical and clinical trials. The company will also focus on advancing the preclinical research of other respiratory allergens (pollens, animal dander) and developing them into vaccines, as well as securing key intellectual property.